ASP.L Regulatory News (ASP)

8 May 2008 07:01

Ascribe plc08 May 2008 Press Release 8 May 2008 Ascribe plc ("Ascribe" or "the Group") Award of eleven ASCC framework contracts Ascribe plc (AIM:ASP), the innovative health IT group, today announces that ithas been successful in its bid to supply Clinical Information Technology (CIT)services through the UK National Health Service's National Program for IT ASCC('Additional Supply Capability and Capacity') Framework Agreement. This givesthe Group's customers the ability to order CIT services through a frameworkagreement directly from Ascribe or through a number of partners, such as BT andCSC, over a four year period. Commenting on the ASCC, Stephen Critchlow, Executive Chairman of Ascribe, said:"This is a great achievement and I am delighted to say that, between Ascribe andour closest partners, the Group's products and services - including those fromour key markets, Accident and Emergency, hospital pharmacy, electronicprescribing and mental health - are on the approved list. The ASCC FrameworkAgreement adds another option to our English NHS customers for the procurementof services and we look forward to the opportunity of supplying through thisroute. The catalogue will provide local purchasers within the English NHSgreater autonomy to make healthcare IT decisions. Our order book has alreadygrown to record levels from local procurement outside of the National Programand now that Ascribe has been included on the ASCC, we expect our order pipelineto grow further still." Ascribe is the market leader in Medicines Management IT, focussing on solutionsthat directly improve clinical safety and patient care. Over 50% of UKhospitals use the Group's pharmacy systems and it now offers solutions to over25% of mental health departments and 30% of Accident and Emergency departments.Furthermore, Ascribe's solutions are installed internationally in Australia, NewZealand, Hong Kong, Republic of Ireland and Malaysia. The ASCC can be used to support both National Programme for IT related work andwider healthcare IT projects. - Ends - For further information please contact:Ascribe plc Stephen Critchlow, Executive Chairman Tel: : +44 (0) 870 053 4545 stephen.critchlow@ascribe.com www.ascribe.comJeremy Lee, Finance Director Tel: : +44 (0) 870 053 4545 jeremy.lee@ascribe.com www.ascribe.com Investment enquiries:Cenkos Ian Soanes Tel: +44 (0) 20 7397 8900 isoanes@cenkos.com www.cenkos.com Media enquiries:Abchurch Stephanie Cuthbert / Justin Heath Tel: +44 (0) 20 7398 7718stephanie.cuthbert@abchurch-group.com www.abchurch-group.com Notes to Editors Ascribe plc is a leading healthcare company that develops and markets softwaresolutions supporting patient, clinical and business processes to Primary &Secondary healthcare providers in the UK and overseas. Ascribe is committed to providing technologies that improve patient safetystandards and the company's solutions directly improve patient care and deliverfinancial savings to customers. The Group sells directly to hospitals andPrimary Care Trusts. Ascribe's technology enables customers to report morethoroughly on patient care and also benefits patients by seamlessly contributingto their electronic health care record. The Group provides solutions to clinical professionals in all healthcaresectors; customers include Emergency and Minor Injuries Units, Mental Health andSocial Care Units, Hospitals requiring patient administration systems (PAS) andmedical equipment management, Hospital and Retail Pharmacies, and GeneralPractice surgeries. Offering patient and decision support information to theseclinicians in context with their activity is the key to the company's ongoingsuccess. Ascribe plc was floated on AIM in 2004, and currently employs over 220 personnelthrough its operating companies in the UK, Kenya, Australia and New Zealand. Formore information, please visit www.ascribe.com (c) Ascribe 2008. Ascribe is a registered trademark of Ascribe plc. All otherbrands and product names and trademarks are the registered property of theirrespective companies. This information is provided by RNS The company news service from the London Stock Exchange